Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Aging on Vaccine Responses (SLVP033)
NCT03312699Phase 1Completed
- Sponsor
- Stanford University
- Start
- Sep 2017
- Primary completion
- Dec 2023
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated), influenza virus vaccine, split virion, Fluzone Trivalent, Hepatitis A virus vaccine, salmonella typhi capsular polysaccharide vaccine and 1 more in influenza, hepatitis A (HAV) and typhoid fever (8 arms), sponsored by Stanford University. Primary endpoint: Hemagglutination Inhibition Assay Titers at Day 28. Started Sep 2017; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)influenza virus vaccine, split virionFluzone TrivalentHepatitis A virus vaccinesalmonella typhi capsular polysaccharide vaccine
03
Conditions
influenzahepatitis A (HAV)typhoid fever
Beyond the preview
Go deeper on NCT03312699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312699.